To allow a direct comparison with our previous work on MZC in the single infection model,36 p27 ELISA was used as a readout. MZC (1:100 and 1:300 dilutions) strongly inhibited SHIV-RT infection relative to untreated (medium) and CG controls (SOFT/CUM, 90%–99% inhibition, P < 0.0001/0.05) (Fig. 3B). MZC and CG at 1:100 dilution (SOFT/CUM, 99% inhibition, P < 0.0001) and CG at 1:300 dilution (SOFT/CUM, >90% inhibition, P < 0.05) inhibited HSV-2 vs. untreated control, pointing to CG-mediated activity of MZC against HSV-2.
1. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;19:61–77.
2. Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res. 2012;10:228–237.
3. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73–83.
4. Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2
serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis. 2009;199:958–964.
5. Glynn JR, Carael M, Auvert B, et al. Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. AIDS. 2001;15(suppl 4):S51–S60.
6. Duffus WA, Mermin J, Bunnell R, et al. Chronic herpes simplex virus type-2 infection and HIV viral load. Int J STD AIDS. 2005;16:733–735.
7. Gray RH, Li X, Wawer MJ, et al. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis. 2004;189:1209–1215.
8. Mole L, Ripich S, Margolis D, et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 1997;176:766–770.
9. Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med. 1995;123:845–847.
10. Wright PW, Hoesley CJ, Squires KE, et al. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis. 2003;36:207–211.
11. Corey L, Wald A, Celum CL, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435–445.
12. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One. 2008;3:e2230.
13. Goode D, Truong R, Villegas G, et al. HSV-2
-driven increase in the expression of alpha4beta7 correlates with increased susceptibility to vaginal
SHIV(SF162P3) infection. PLoS Pathog. 2014;10:e1004567.
14. Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008;9:301–309.
15. Cicala C, Martinelli E, McNally JP, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A. 2009;106:20877–20882.
16. Kader M, Wang X, Piatak M, et al. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol. 2009;2:439–449.
17. Martinelli E, Veglia F, Goode D, et al. The frequency of alpha(4)beta(7)(high) memory CD4(+) T cells correlates with susceptibility to rectal
simian immunodeficiency virus infection. J Acquir Immune Defic Syndr. 2013;64:325–331.
18. Ansari AA, Reimann KA, Mayne AE, et al. Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol. 2011;186:1044–1059.
19. Martinelli E, Tharinger H, Frank I, et al. HSV-2
infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathog. 2011;7:e1002109.
20. Houlihan CF, Larke NL, Watson-Jones D, et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS. 2012;26:2211–2222.
21. Ng'ayo MO, Bukusi E, Rowhani-Rahbar A, et al. Epidemiology of human papillomavirus infection among fishermen along lake Victoria Shore in the Kisumu District, Kenya. Sex Transm Infect. 2008;84:62–66.
22. Marais DJ, Passmore JA, Denny L, et al. Cervical and oral human papillomavirus types in HIV-1 positive and negative women with cervical disease in South Africa. J Med Virol. 2008;80:953–959.
23. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, et al. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer. 2006;95:355–362.
24. Safaeian M, Kiddugavu M, Gravitt PE, et al. Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev. 2008;17:1300–1307.
25. Lissouba P, Van de Perre P, Auvert B. Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2013;89:350–356.
26. Fernandez-Romero JA, Deal C, Herold BC, et al. Multipurpose prevention technologies: the future of HIV and STI protection. Trends Microbiol. 2015;23:429–436.
27. Fernandez-Romero JA, Teleshova N, Zydowsky TM, et al. Preclinical assessments of vaginal
microbicide candidate safety and efficacy. Adv Drug Deliv Rev. 2015;92:27–38.
28. Malcolm RK, Boyd P, McCoy CF, et al. Beyond HIV microbicides: multipurpose prevention technology
products. BJOG. 2014;121(suppl 5):62–69.
29. Kenney J, Aravantinou M, Singer R, et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal
SHIV infection in macaques. PLoS One. 2011;6:e15835.
30. Kenney J, Singer R, Derby N, et al. A single dose of a MIV-150
/Zinc acetate gel provides 24 h of protection against vaginal
simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8–24 h after gel use. AIDS Res Hum Retroviruses. 2012;28:1476–1484.
31. Kizima L, Rodriguez A, Kenney J, et al. A potent combination microbicide that targets SHIV-RT
and HPV. PLoS One. 2014;9:e94547.
32. Hsu M, Aravantinou M, Menon R, et al. A combination microbicide gel protects macaques against vaginal
simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge. AIDS Res Hum Retroviruses. 2014;30:174–183.
33. Kenney J, Derby N, Aravantinou M, et al. Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides. AIDS Res Hum Retroviruses. 2014;30:1117–1124.
34. Levendosky K, Mizenina O, Martinelli E, et al. Griffithsin and carrageenan combination to target HSV-2
and HPV. Antimicrob Agents Chemother. 2015.
35. Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007;13:857–861.
36. Barnable P, Calenda G, Ouattara L, et al. A MIV-150
/zinc acetate gel inhibits SHIV-RT
infection in macaque vaginal
explants. PLos One. 2014;9:e108109.
37. Barnable P, Calenda G, Bonnaire T, et al. MIV-150
/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal
explant model. Antimicrob Agents Chemother. 2015;59:3829–3837.
38. Friedland B, Plagianos, Zhang, et al. A First-in-Human Trial of PC-1005 (MIV-150
and Zinc Acetate in a Carrageenan Gel). CROI 2016; February 22-25, 2016; Boston, MA. Abstract 875.
39. Richardson-Harman N, Mauck C, McGowan I, et al. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal
safety study. AIDS Res Hum Retroviruses. 2012;28:1422–1433.
40. Ouattara LA, Barnable P, Mawson P, et al. MIV-150
containing intravaginal rings protect macaque vaginal
explants against SHIV-RT
infection. Antimicrob Agents Chemother. 2014.
41. Introini A, Vanpouille C, Grivel JC, et al. An ex vivo Model of HIV-1 Infection in Human Lymphoid Tissue and Cervico-vaginal
Tissue. Bio Protoc. 2014;4.
42. Abner SR, Guenthner PC, Guarner J, et al. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis. 2005;192:1545–1556.
43. Animal Welfare Act and Regulation of 2001. ed. Code of Federal Regulations, t., Chapter 1, Subchapter A: Animals and Animal Products. U.S. Department of Agriculture, Beltsville, MD.
44. Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources Guide for the Care and Use of Laboratory Animals. Vol 85-23. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 1985:1–83.
45. Singer R, Mawson P, Derby N, et al. An intravaginal ring that releases the NNRTI MIV-150
reduces SHIV transmission in macaques. Sci Transl Med. 2012;4:150ra123.
46. Turville SG, Aravantinou M, Miller T, et al. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One. 2008;3:e3162.
47. Fernandez-Romero JA, Abraham CJ, Rodriguez A, et al. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal
challenge. Antimicrob Agents Chemother. 2012;56:358–368.
48. Ammerman NC, Beier-Sexton M, Azad AF. Growth and maintenance of Vero cell lines. Curr Protoc Microbiol. 2008; Appendix 4:Appendix 4E.
49. McDermott MR, Smiley JR, Leslie P, et al. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol. 1984;51:747–753.
50. Ashley R. Chapter 22: diagnostic procedures for viral, rickettsial, and chlamydial infections. In: Schmidt NJ, Emmons RW, eds. Washington, DC: American Public Health Association; 1995.
51. Aravantinou M, Singer R, Derby N, et al. The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. AIDS Res Hum Retroviruses. 2012;28:1467–1475.
52. Luciw PA, Shaw KE, Unger RE, et al. Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS Res Hum Retroviruses. 1992;8:395–402.
53. Legoff J, Bouhlal H, Gresenguet G, et al. Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfected with HSV and HIV. J Clin Microbiol. 2006;44:423–432.
54. Richardson-Harman N, Lackman-Smith C, Fletcher PS, et al. Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol. 2009;47:3530–3539.
55. Rollenhagen C, Lathrop MJ, Macura SL, et al. Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides. Mucosal Immunol. 2014.
56. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2
infection. JAMA. 2011;305:1441–1449.
57. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. J Acquir Immune Defic Syndr. 2010;54:482–488.
58. Vanden Oever MJ, Han JY. Caspase 9 is essential for herpes simplex virus type 2-induced apoptosis in T cells. J Virol. 2010;84:3116–3120.
59. Stefanidou M, Ramos I, Mas Casullo V, et al. Herpes simplex virus 2 (HSV-2
) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy. J Virol. 2013;87:1443–1453.
60. Peretti S, Shaw A, Blanchard J, et al. Immunomodulatory effects of HSV-2
infection on immature macaque dendritic cells modify innate and adaptive responses. Blood. 2005;106:1305–1313.
61. Guerra-Perez N, Aravantinou M, Veglia F, et al. Rectal HSV-2
infection may increase rectal
SIV acquisition even in the Context of SIVDeltanef vaccination. PLoS One. 2016;11:e0149491.
62. Janocko L, Althouse AD, Brand RM, et al. The molecular characterization of intestinal explant HIV infection using Polymerase Chain Reaction-Based Techniques. AIDS Res Hum Retroviruses. 2015;31:981–991.
63. Kenney J, Rodriguez A, Kizima L, et al. A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo. Antimicrob Agents Chemother. 2013;57:4001–4009.